REMINDER: Our user survey closes TODAY, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,370.00
Bid: 12,370.00
Ask: 12,374.00
Change: 38.00 (0.31%)
Spread: 4.00 (0.032%)
Open: 12,350.00
High: 12,432.00
Low: 12,314.00
Prev. Close: 12,332.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-WHO says vaccine makers working non-stop to plug supply gap, urges patience

Thu, 28th Jan 2021 10:23

(Adds quote from WHO Europe vaccination expert)

* WHO urges solidarity amid vaccine rollout 'teething
problems'

* EU, Britain clash over delays in promised vaccine supply

* WHO's Kluge hopes 'extra future production' eases delays

* Russian vaccine data bound for Geneva -WHO Europe boss

By Stephanie Nebehay and John Miller

GENEVA, Jan 28 (Reuters) - The World Health Organization's
Europe director Hans Kluge said on Thursday vaccine
manufacturers were working non-stop to plug shortfalls in
supplies to countries struggling to contain the COVID-19
pandemic and urged them not to jostle for deliveries.

"Solidarity does not necessarily mean that each country in
the world starts (vaccinating) at exactly the same moment ...
The good understanding is that no one is safe before everyone is
safe," Kluge told an online news briefing.

Asked about delays in expediting Pfizer and
AstraZeneca vaccines to patients across the 27-nation
European Union, Kluge and a WHO-Europe vaccination expert,
Siddhartha Datta, appealed to governments and manufacturers to
cooperate in addressing "teething problems" in the rollout.

"The reality is there is a shortage of vaccines...(But) we
don't doubt that manufacturers and producers are working 24-7 to
bridge the gaps and we're confident the delays we are seeing now
are going to be made up by extra production in the future,"
Kluge said.

The WHO reiterated that vaccines should be shared equitably,
between poor and rich nations, to help end the pandemic with
Datta stressing COVID-19 vaccines were "a global public good".

As Kluge and Datta spoke, Europe's fight to secure COVID-19
vaccine supplies escalated as Britain demanded that it receive
all the shots it paid for after the EU asked AstraZeneca to
divert supplies from the UK.

The EU, whose members are far behind Israel, the United
Kingdom and the United States in dispensing vaccines, is
scrambling to obtain shots just as the West's biggest drugmakers
slow deliveries to the bloc due to production problems.

"We need to be patient, it will take time to vaccinate,"
Kluge said, adding that a total of 35 countries in Europe had
launched vaccinations with 25 million does administered so far.

PANDEMIC PARADOX

"This paradox, where communities sense an end is in sight
with the vaccine but, at the same time, are called to adhere to
restrictive measures in the face of a new threat, is causing
tension, angst, fatigue, and confusion. This is completely
understandable in these circumstances."

Kluge said continued high rates of transmission and emerging
variants of the virus made it urgent to vaccinate priority
groups, but acknowledged the rate of vaccine production and
distribution was not yet up to expectations.

He reiterated the WHO's stance that "vaccination passports"
- proof that somebody has been inoculated - will be important to
monitor inoculation coverage and efficacy of shots, but should
not be used as a litmus test for allowing people to travel.

Asked about WHO's scrutiny of Russia's Sputnik V vaccine,
Kluge said he had spoken with Moscow's ambassador on Wednesday
and that he could confirm that data needed by WHO scientists to
review the shot was en route to Geneva where the WHO is based.

The Russian vaccine is being distributed in Europe including
EU member state Hungary as well as elsewhere in the world, even
though the European Medicines Agency is not currently reviewing
it for approval.
(Reporting by Stephanie Nebehay and John Miller
Editing by Mark Heinrich)

More News
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.